Research programme: diagnostic imaging - Bracco/Takeda
Latest Information Update: 15 Jan 2019
At a glance
- Originator Bracco; Dyax
- Developer Bracco; Shire
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined(Diagnosis) in USA
- 22 Jan 2016 Dyax has been acquired by and merged into Shire